Graft failure is a common and severe complication of unrelated donor bone marrow transplantation (UD-BMT). However, there are few reports of a second UD-BMT in this setting. We describe 12 patients with graft failure (five primary, seven secondary) who had a second transplant, five from their original donor and seven from a different donor. Their median age was 9 years. Two patients died before day 10 of regimenrelated toxicity. Nine of 10 evaluable patients engrafted in a median of 17 days. Secondary graft failure was seen in one patient. Transplant-related morbidity was significant. Six of nine developed acute GHVD, there were five severe infections and five patients developed Bearman grade 3 or 4 extramedullary toxicity. Overall, five patients survive at a median of 38 months after the second BMT and two are in continuous complete remission. Second transplants from unrelated donors for graft failure can result in prolonged survival.
Graft failure constitutes one of the most important reasons for treatment failure following unrelated donor BMT (UD-BMT). It occurred in 14% of patients reported from the National Marrow Donor Program 1 study but in only 4% of non-T cell-depleted grafts reported by the Seattle Team. 2 It can be either primary or occur secondarily after initial engraftment, although both have a poor outcome. Risk factors may include donor-recipient mismatch, 3 prior alloimmunization, less intense conditioning regimens, the use of T cell depletion, 1 a low marrow cell dose 4 and HLA-C mismatch. 5 Graft failure is particularly troublesome in the UD setting. By the time it is recognisable, the patient has usually been pancytopenic (often with a neutrophil count of zero) for 2-3 weeks, and is often in poor clinical condition and at high risk of fungal infection. Obtaining access to the original donor may present logistic and ethical problems and the delays in securing further stem cells or working- up and harvesting the marrow of another donor often prove costly. There is no guarantee of engraftment after a second BMT and the conditioning therapy required is usually very toxic.
There have been only a few reports where stem cells from an unrelated donor were used to treat graft failure following an initial UD-BMT; consequently the outcome is not known. Here we describe 12 such patients, five of whom survive at a median of 38 months from their second BMT.
Patients and methods

The 12 patients in this series all received ex vivo T celldepleted marrow from unrelated donors and were transplanted at the BMT unit at the Bristol Royal Hospital for Sick Children between June 1990 and November 1994. The diagnoses and clinical characteristics of the first transplant procedure are shown in Table 1 . Two thirds of patients were transplanted for leukaemia and half were high risk candidates (see below). There were more males than females and the median age was 8.5 years. The median cell dose was 5.6 × 10 8 /kg recipient weight. Two thirds of donor-recipient pairs were molecular matches at HLA-A, -B, -DR and DQ loci and four patients were single antigen mismatches (three class I and one class II). The methods of performing tissue typing have been described previously. 6 
Preparative regimen and GVHD prophylaxis for the first transplant
All patients received Campath 1G 5-20 mg i.v. on days −9 to −5 in an attempt to prevent graft failure. Seven patients received standard conditioning with 120 mg/kg cyclophosphamide (days −6 and −5), 1440 cGy total body irradiation (in eight fractions, days −3 to 0) and 5 days of Campath 1G at days −9 to −5.
6 Two patients received busulphan (16-20 mg/kg) and cyclophosphamide (200 mg/kg) and the two children with Fanconi's anaemia received 40 mg/kg cyclophosphamide, and 150 cGy TBI per day for 4 days. The remaining patient was given 200 mg/kg cyclophosphamide and total nodal irradiation. All patients received cyclosporine 6 and three patients with class I mismatched donors received methotrexate as additional GVHD prophylaxis. Nine patients received Campath 1G i.v. pre-transplant and four patients had methotrexate as GVHD prophylaxis. Cy/TBI = cyclophosphamide 120 mg/kg plus 14.4 Gy TBI in eight fractions. The dose of cyclophosphamide is 120 mg/kg unless otherwise specified. Bu16 = busulphan 16 mg/kg in 4 days. Type of graft failure, P = primary and S = secondary. SAA = severe aplastic anaemia; TNI = total nodal irradiation; NE = not evaluable; ALG = antilymphocyte globulin; S = skin; G = gut; L = liver; + = continuing survival.
Definitions
Primary graft failure is the failure to achieve a neutrophil count of 0.5 × 10 9 /l for 3 consecutive days and secondary graft failure is persistent severe neutropenia (Ͻ0.1 × 10 9 /l) occurring after primary engraftment or silent rejection as shown by cytogenetic studies or a shift in chimerism towards recipient status. 7 Standard risk patients comprised those with leukaemia in remission or CML in chronic phase; Ph-positive ALL was categorized as at high risk. Patients with Fanconi's anaemia, and a highly sensitised patient with severe aplastic anaemia were placed in the high risk group. A patient with late infantile Batten disease was considered low risk. 8 The five patients with primary graft failure all had extremely hypocellular marrow aspirates and trephines; three had a neutrophil count of 0 and two achieved a maximum neutrophil count of 0.1 × 10 9 /l. All seven patients with secondary graft failure had markedly hypocellular marrows. Two had neutrophil counts of 0 and two had cytogenetic or chimerism evidence of donor haematopoiesis. The remaining three patients had maximum neutrophil counts of 0.1 to 0.3 × 10 9 /l, but these counts were only achieved with G-CSF and there was a trend towards worsening hypocellularity. It was felt in this setting that the infusion of further cells without conditioning would be unsuccessful.
Results
Clinical characteristics of the second transplant
The median interval between the two transplants was short; this duration influenced the intensity of the second preparative regimen. In seven cases the second donor was different to the donor for the first transplant (Table 1) . Six patients had HLA mismatches with their second donor (three single class I mismatches, one double class I antigen mismatch, one class II mismatch and one class I and class II mismatch).
Conditioning was varied and partly depended on whether TBI was used for the first transplant and on the clinical condition of the patient. No patient had ex vivo T cell depletion of the second marrow. Ten patients had CAM-PATH 1G pre-transplant and one patient had ALG pretransplant. Five patients received busulphan 16 mg/kg and cyclophosphamide 200 mg/kg. Four of these were after an initial cyclophosphamide/TBI regimen and one after a previous busulphan/cyclophosphamide regimen. All these patients had Campath 1G in addition from day −9 to −5; one only had further Campath 1G from day 0-+5. Two further patients received cyclophosphamide/TBI conditioning after an initial busulphan/cyclophosphamide regimen. One of these had Campath 1G in addition, the other had ALG instead (day −11 to −7 inclusive). Three patients who were receiving marrow from the same donor were conditioned with cyclophosphamide 120 mg/kg and Campath 1G. One of the two remaining patients received cyclophosphamide 40 mg/kg and Campath 1G, the other just cyclophosphamide 80 mg/kg and no Campath, respectively. The median cell dose was 5.7 × 10 8 /kg recipient weight (range 2.7-13.0).
Engraftment
Two of the patients died before day 10 and are not evaluable for engraftment. Nine patients (90%) engrafted primarily from their second BMT at a median time of 17 days (range 12-39). Secondary graft failure occurred in one of nine patients at day +56. This patient required infusion of autologous stem cells which promptly engrafted. One patient (who was fully matched with his donor) failed to engraft and died on day 42 from presumed fungal infection.
Survival and disease status
Five patients survive at 21-66 months from the second transplant (mean 38 months). Two patients (ALL and juvenile CML) are in continuous complete remission. Two patients have relapsed; one patient with CML who required autologous rescue has relapsed cytogenetically but has normal peripheral blood counts and one patient with Ph-positive ALL relapsed 2 years post-transplant, but has since received donor leucocyte infusions which resulted in a complete remission lasting 7 months and chronic GHVD. This patient recently suffered a further relapse and received another course of donor leucocytes. The fifth patient, with Batten's disease, is alive but is deteriorating neurologically. Seven patients died. In two, the cause was relapse and in five, transplant-related toxicity. Three of six patients who received marrow from the same donor are alive, compared to two of six who received marrow from a different donor (P = NS).
Graft-versus-host disease
Six out of the nine patients (67%) who engrafted developed acute graft-versus-host disease. In three cases this was grade I-II GVHD of the skin only. Two of the remaining patients had histologically proven gut GVHD in addition to skin, and the remaining patient had skin and probable liver GVHD. Five patients survived 100 days and are evaluable for chronic GVHD. One patient (20%) has extensive chronic GVHD of the skin, gut and lung.
Infection
Three patients had proven aspergillus infection (two pulmonary, one hepatic). A patient with hepatic involvement responded to amphotericin and is alive and well. One patient with pulmonary involvement required surgical removal of the aspergillus cavity and also remains well. The remaining patient developed pulmonary aspergillosis soon after the second stem cell infusion and died on day 8. Two further patients developed severe CMV infection (one retina, one blood) and neither of them survived. One patient with failure of the second graft died at day 42 from presumed infection but no organism was isolated.
Regimen-related toxicity
All patients were considered evaluable for regimen-related toxicity (RRT). RRT was graded according to the criteria of Bearman and colleagues. 9 Severe RRT (grade 3-4) was seen in a total of five out of 12 patients (42%). Two patients experienced severe bladder toxicity (grade 3 + 4). One patient developed grade 4 cardiac toxicity. Another patient died of multiorgan failure with severe impairment of pulmonary, renal and hepatic function. Grade 3 CNS toxicity was seen in one further patient. Of these five patients with severe RRT, three received full-dose conditioning for the second transplant and two had reduced doses. The median interval between transplants in the patients with severe RRT did not differ from the group without severe RRT.
Performance status of survivors
Three of the survivors remain physically well with a good performance status. Two are in full-time education and one is currently looking for full-time work. One patient is markedly affected by GVHD of the skin, gut and lungs. This patient is on long-term steroids and requires home oxygen therapy. The patient with Batten disease has progressive neurological deterioration but possibly at a slower pace than may have been expected.
Discussion
Primary graft failure is a devastating complication of UD-BMT. The patient is often febrile and very ill because of prolonged severe neutropenia and superadded fungal infection. Secondary graft failure is also a difficult management problem, although the duration and severity of neutropenia may be less. In 140 consecutive patients who received UD-BMT for ALL in Bristol the incidence of graft failure was 5% in full matches and 14% in mismatched grafts (Oakhill, unpublished observations) . Overall, the outcome of second transplants is poor. The IBMTR reported only a 7% disease-free survival and a nearly 70% transplant related mortality in patients transplanted within 6 months of the initial transplant. 10 Less intensive conditioning has been reported to result in lower transplant-related mortality. 11 The Minneapolis group reported 33 patients (five who had UD-BMT) with primary and secondary graft failure who were treated with second infusions of marrow. About 50% engrafted but only 25% survived 1 year. 12 The most reliable and quick way of restoring marrow function is by reinfusion of autologous back-up cells if these have been stored. However, this often means early disease recurrence, and many patients may be unwilling to proceed with this form of treatment. The other possibility is to obtain further cells from the same or a different unrelated donor. This often presents considerable practical difficulties. The original donor may be unwilling or unavailable to donate further cells and there is usually very little time to identify, work-up and harvest an alternative unrelated donor. Even if these practical difficulties can be overcome, a second conditioning regimen is often very toxic and there is no guarantee of engraftment the second time around. Some groups advocate the use of peripheral blood stem cells to treat graft failure as a higher progenitor cell dose can usually be delivered and the period of neutropenia may be shortened. 13 This strategy is not available in the UK at present and the ethics of administering G-CSF to unrelated donors in the UK is currently being debated.
In this report we show that high rates of engraftment can be achieved with a second unrelated donor transplant. Five patients have enjoyed long-term survival from the time of graft failure, although only two of them are likely to be cured. GVHD and RRT are, as expected, major problems. T cell depletion is a major risk factor for graft failure so it seems logical to omit TCD in a second UD-BMT where the first transplant was complicated by graft failure. A high rate of acute GVHD is expected after non-TCD UD-BMT, especially where there is a degree of mismatch.
Another difficult decision relates to the second conditioning regimen. It is difficult to avoid giving a highly immunosuppressive and toxic regimen and considerable RRT is probably unavoidable in this situation. Another decision relates to the choice of second donor. If an alternative, better matched donor is rapidly available, then that donor is generally chosen but in many cases just giving further unmanipulated cells from the same donor will suffice.
In summary, a second UD transplant can result in prolonged survival for patients with primary graft failure and should be considered in situations such as high-risk leukaemia, Fanconi's anaemia or aplastic anaemia where autologous reinfusion is not possible or undesirable. The strength of conditioning used should depend on the patient's clinical state and the time between transplants. Our experience suggests that avoiding ex vivo T cell depletion in the second transplant can result in a high rate of engraftment. Nonetheless, these second transplants are often difficult procedures and the requirements for supportive care are high. Finally, the ability to contemplate a second UD transplant necessitates rapid access to the original donor or an ability to rapidly work up an alternative donor.
